Navigation Links
Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage

THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1).  Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.

The patent broadly protects the formation or repair of cartilage when applying a NELL-1 sequence of UCB-1 in a region where cartilage formation or repair is desired to include the method of application comprising a variety of delivery agents in surgical applications.  

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. credited the company's partner, the Musculoskeletal Transplant Foundation (MTF) for its ongoing financial and strategic support. "MTF is essential to our progress toward realizing the full potential of the UCB-1 protein as a platform technology."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):